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Abstract
Background: To evaluate the effect of a dietary supplement containing polyunsaturated fatty acids, in association with 
Humulus lupulus extract, on the quality of sleep using the Leeds sleep evaluation questionnaire (LSEQ) in subjects with 
moderate to severe sleep disorders.
Methods: Randomized placebo-controlled trial, in a Population-based setting. Participants were adult patients 25 to 65 
years old with a chronic primary insomnia who volunteered for the study. The tested intervention consisted of two soft 
gelatine capsules per day, containing either the dietary supplement (active group) or olive oil (placebo group) for a 
month. Subjects could also volunteer for two ancillary studies on melatonin and actigraphy. Evaluation criteria 
included i) perception of the quality of sleep at the end of treatment using the LSEQ questionnaire, ii) sleep efficiency 
measured by one-week actigraphic movement measurement performed before and during the treatment in a 
subsample of subjects, iii) night melatonin and 6 sulfatoxymelatonin (aMT6S) urine rates in a subsample of subjects.
Results: The average of Leeds score was similar in both groups (p = 0.95). A marked improvement in the quality of 
sleep was observed in both placebo (62%) and active (65%) group (p = 0.52). The evolution of urinary melatonin, 
aMT6S, and of the Mel/aMT6S ratio showed no differences between the two groups. Sleep efficiency, as measured by 
actigraphy, improved similarly in both groups during the treatment period, from 72% to 76% and 75% in the active and 
placebo group respectively (p = 0.91).
Conclusions: The dietary supplement had neither effect on the perceived quality of sleep, nor on the melatonin 
metabolism and sleep-wake cycle.
Trial registration: clinical trials.gov:NCT00484497
Background
The estimated incidence of primary insomnia in the gen-
eral population is 10 to 20% [1-3]. The consequences of
this disorder are an impaired quality of life, an increase in
medical consultations and in hypnotic drug consumption
[4]. Increase in drug consumption reinforces the risk of
work accident and absenteeism, resulting in a decrease in
productivity [1,2]. It can also leads to adverse cognitive
and psychomotor effects, daytime sleepiness [5], loss of
memory, increased risk of falling in old subjects [6], and
impaired driving abilities [7]. Alternative therapeutics
would therefore be welcome.
Melatonin, a hormone produced mostly during the
night by the pineal gland, displays the role of an endoge-
nous synchronizer, especially on the sleep-wake cycle [8].
Melatonin receptors are present at the level of the endog-
enous circadian clock located in the suprachiasmatic
nuclei.
The study product is a dietary supplement composed of
natural components. It contained a specific ratio of poly-
unsaturated fatty acids (PUFA, linolenic and linoleic
acids), in association with Humulus lupulus extract.
PUFA were claimed to favor melatonin synthesis [9]. The
short half-life of melatonin requires the administration of
high doses to balance its quick metabolism. Recently, a
controlled release melatonin preparation has been shown
effective in insomnia in aged patients [10-13]. Humulus
lupulus extract has been shown to decrease the hepatic
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metabolism of drugs which are metabolised by the
CYP1A2, a cytochrome that also allows melatonin trans-
formation into its main metabolite: 6 sulfatoxymelatonin
(aMT6s) [10]. This combined action could increase mela-
tonin bioavailability and is likely to reset the endogenous
biological clock. Besides, Humulus lupulus extract could
directly act on sleep by enhancing the melatonin-medi-
ated effects on the sleep-wake cycle [10].
Our objective was to evaluate the effect of the dietary
supplement on the quality of sleep using the Leeds sleep
evaluation questionnaire (LSEQ) in adult subjects with
moderate to severe primary insomnia in a prospective
double blind, randomized, placebo-controlled clinical
trial.
Methods
Study population
Overall, 101 patients were enrolled between September
2006 and June 2007. The study was carried out at the
Clinical Investigation Centre (CIC) located at the Lyon
university hospital (France).
Subjects were invited to volunteer for the study through
press announcements and a website for healthy volun-
teers' recruitment http://www.volterys.fr/. On the day of
enrolment, subjects had a medical visit and a written con-
sent was obtained after further information has been
given.
The study was conducted in accordance with the Decla-
ration of Helsinki. The protocol was approved by Lyon
Ethics Committee (Comité de Protection des Personnes
Lyon B) on July 18th 2006.
The study design is shown in Figure 1. In addition to
the main study, subjects could volunteer for two ancillary
studies before randomization. The first ancillary study
was based on overnight urinary melatonin and aMT6s
measurements (melatonin sub-study) and the second, a
one-week actigraphic movement measurement (Acti-
graphic sub-study).
Men and women aged 25 to 65 years, with a chronic
primary insomnia were eligible to participate to the main
study. Subjects had to be affiliated to the French Social
Security System. Primary insomnia was defined accord-
ing to the Diagnostic and Statistical Manual of Mental
Disorders [14] (DSM-IV) and the International Classifi-
cation of Sleep Disorders [15]. The severity of insomnia
was classified by using the Insomnia Severity Index (ISI)
[16]. The baseline minimum inclusion ISI score was 12,
but was changed to strictly superior to 10 on February 6th,
2007, due to recruitment difficulties.
Exclusion criteria
Sleep disorders secondary to another health problem;
pharmacological resistance to common hypnotic drugs;
any ongoing long term treatment (except contraceptive
and postmenopausal hormone replacement); acute dis-
ease during the previous three months; medical history
that could interfere with sleep; history of psychiatric dis-
order in the five years preceding the inclusion (detected
using the MINI questionnaire) [17], depressive disorder
measured by a score above 30 (or identification of a risk
of suicide) on the Beck self-questionnaire [18], pregnant
or lactating women; subjects for whom a poor adherence
to the study protocol can be anticipated (i.e. likely to leave
the study area); individuals protected by law; lifestyle
habits which would modify the wake-sleep rhythm (e.g.
night work), or which would be likely to be modified dur-
ing the study period; known allergy to one of the dietary
supplement components; subjects with excessive daytime
sleepiness as measured by an Epworth score equal to or
superior to ten [19].
Randomization/intervention
A permuted-block algorithm was used for randomiza-
tion. Concealed allocation was performed by the coordi-
nation centre after eligibility check and baseline data
collection. Patients were asked to take two soft gelatine
capsules per day two hours before sleep for a month. Cap-
sules contained the dietary supplement (active group) or
olive oil (placebo group). The dietary supplement is cur-
rently on the market under the brand name Cyclamax®
and contains 260 mg Soya oil (Glycine max), 173 mg.
Cade oil (Cannabis sativa), 50 mg Houblon (Humulus
lupulus) and 6 mg Soya lecithin. Its envelope is composed
of modified starch, glycerine, Iota carrageenan, glyceryl
monostearate, titanium dioxide, lecithin certified non-
GMO, and disodium phosphate.
Evaluation criteria and follow-up
The primary criterion was to evaluate the perception of
the quality of sleep at the end of the treatment (D30)
using the LSEQ questionnaire [20]. This is a standardized
self-reporting instrument comprising ten 100-mm visual
analogue quetions that pertain to four items: i) the ease of
getting to sleep (GTS, items 1-3), ii) the quality of sleep
(QOS, items 4, 5), iii) awakening from sleep (AFS, items
Figure 1 Study design.
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6, 7) and iv) behaviour following wakefulness (BFW,
items 8-10). The LSEQ is a sensitive indicator of subjec-
tively felt changes in sleep latency, and sleep quality. For
each question, the subject responds by placing a vertical
mark on the line (0-100 mm) to indicate his/her present
self-evaluation. The position of the mark indicates the
nature and extent of the change, i.e. the middle of the line
indicates no change, and the larger the changes the closer
to the end of the line (improvement on the left, and
impairement on the right). The score has been used in
acute and chronic regimens. LSEQ was measured at day
30, and day 46 [11,12,21].
Secondary criteria included the LSEQ at day 46 (D46).
Other measurements
A daily sleep diary was recorded by the participants to
obtain information on total sleep duration, duration of
first sleep (i.e. duration of sleep till the first awakening),
number and duration of night wakes, number and dura-
tion of day sleep. Sleep efficiency (duration of sleep/time
spent in bed) was then computed.
The patients' evolution was rated by the investigator,
using the Clinical Global Impression at entry and the
Clinical global impression change (from very much better
to very much worse) between inclusion, D30 and D46.
Safety was measured by recording adverse events.
Screening characteristics measured only at baseline
included medical history,` the Insomnia Severity Index
(ISI) questionnaires, a MINI questionnaire for psychiatric
disorders screening, results, the Beck Depression Index
17, sleep characteristics, Epworth Sleepness Scale,), and
the morningness-eveningness questionnaire of Horne
and Ostberg which evaluates diurnal preference [16-
19,22].
Follow-up included questionnaires on D30, evolution
of symptoms and compliance to treatment (number of
pills used assessed by pill count/number of study days). A
follow-up visit was performed on D46 to assess a poten-
tial persisting treatment effect.
Melatonin sub-study
The night melatonin and aMT6s urine rates were mea-
sured before and at the end of the treatment. Night urines
were collected from 8:00 PM to 8:00 AM. Total urine vol-
ume was measured and a 5 ml-sample was frozen. Mela-
tonin and aMT6s concentrations were determined using
radio-immunoassays (RIA) [23,24]. Briefly, melatonin
RIA was performed on urine extract using an I125tracer
and a rabbit melatonin antibody. The aMT6s RIA assay
was performed on diluted urine using an I125tracer and a
rabbit melatonin antibody. Results were expressed in
nano-gramme (ng) or pico-gramme (pg) per hour for
aMT6s and melatonin respectively. Melatonin/aMT6s
ratio was also determined.
Actigraphy sub-study
A one-week actigraphic movement measurement was
performed twice, using Actigraph AW4 (actiwatchplus®).
The corresponding software (activity and sleep analysis,
2001, Cambridge Neurotechnology Ltd, UK) allowed
computing sleeping patterns, sleep efficiency, latency,
fragmentation index, and average wake movement.
Patients had to wear the device around their non domi-
nant wrist during the one week period before and while
on treatment.
Data collection
Data were collected on Case Report Forms by the investi-
gators, and entered in a data base using the Clininfo SA
software (Clininfo SA, 99 rue de Gerland, 69007 Lyon,
France).
Sample size
The sample size was calculated according to data given by
Hindmarch [25].
Using a between-group mean score difference of 10
points, a score standard deviation of 15 points, α = 5%,
power = 90%, the number of subjects needed is 100; i.e.,
50 subjects per group.
Statistical Analysis
The main outcome measure comprises four scores rela-
tive to dimension GTS, QOS, AFS, and BFW measured in
each patient. Using a mixed model, we studied the effect
of the treatment on these scores considering them as
repeated measurements in each subject [26]. The objec-
tive was to compare the mean of each score in the control
group to the corresponding mean in the treatment group,
taking into account the high correlation between the four
scores. For example, an individual with a high QOS
would probably have a high BFW too. This correlation
should be taken into account to allow statistical inference
about the means of theses variables.
When analysing such repeated measurements or longi-
tudinal data, the mixed model is the method of reference
because it models explicitly the correlation between the
outcome variables and provides correct statistical infer-
ence. Furthermore, this method allows a simultaneous
testing of the effects of the treatment on the four dimen-
sions through a single test with an alpha risk of 5% (Addi-
tional file 1). The effect of the treatment on sleep
efficiency was also assessed using a mixed model.
The effect on other variables of interest was tested
using Student's test for all continuous variables and
Fisher's exact test for categorical variable.
Results
Overall, 101 subjects were enrolled and randomly
assigned to the active dietary supplement or placebo. The
flow diagram and baseline characteristics of the study
population are shown in Figure 2 and Table 1 respectively.Cornu et al. BMC Complementary and Alternative Medicine 2010, 10:29
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Of the 101 patients randomized, 51 were in the active
group (19 men and 32 women) and 50 (13 men and 37
women) in the placebo group. The mean age was 41 years
(range 25-64). Mean body weight, smoking habits, socio-
professional status and diurnal preference did not differ
between the groups. In both groups, 33% had subliminal,
55% had moderate, and 12% had severe insomnia. Com-
pliance with treatment were 98.3 (SD 10.5) and 97.5 (SD
8.1) in placebo and active group respectively.
Quality of sleep, as assessed by the LSEQ, was available
for 99 patients (2 missing data, one in each group). The
average of Leeds score was similar in both groups (Likeli-
hood Ratio Test = 0.71, p = 0.95): mean GTS 173.9 and
170.5, QOS 124.8 and 120.1, AFS 161.6 and 159.1, and
BFW 118.6 and 118.1 in the placebo group and in the
active group respectively (Table 2). The dietary supple-
ment did not improve sleep compared to the placebo
condition. The results remained unchanged after using
two methods of missing data replacement, the maximum
bias method, and the mean value of the group.
A marked improvement in the quality of sleep was
observed in both groups. We observed correlation
between the four scores (r = 0.52 to 0.79). The high corre-
lation between QOS and BFW (r = 0.755) suggested a
good refreshing sleep. Figure 3 shows the mean of the
scores according to the treatment group and the age of
participants. The apparent divergence of the curves for
very old ages might be due to very old subjects consid-
ered as outliers: three in the active group have a very
good score, and two in the placebo group have a very bad
score. There seems to be no clear relationship between
score and age.
Table 1: Baseline characteristics of the study subjects
Active group (n = 51) Placebo group (n = 50)
Male (%) 19 (37) 13 (26)
Age (mean, range) 40,9 (25,1-64,7) 41,8 (24,9-64,8)
Patient < 40 years 23 (45%) 24 (48%)
Patient > 40 years 28 (55%) 26 (52%)
Mean body weight, kg (range) 67 (46-103) 65,4 (45-99)
Non smokers (%) 35 (69) 32 (64)
Socio-professional status
Intermediate 18 17
Students 11 08
Superior 10 11
Employee 9 13
Retired 3 1
Morningness-eveningness
Quite morning type 23
Rather morning type 13 14
Neither morning, nor evening type 23 23
Rather evening type 96
Quite evening type 44
ISI Score
Score 8 to 14 (Minor insomnia) 17 (33%) 17 (33%)
Score 15 to 21 (Moderate Insomnia) 28 (55%) 28 (55%)
Score 22 to 28 (Severe insomnia) 6 (12%) 5(12%)
ISI score stands for Insomnia Severity index.Cornu et al. BMC Complementary and Alternative Medicine 2010, 10:29
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Secondary criteria analyses
Secondary results are shown in the table 3. The D46 anal-
ysis was not performed because a persisting treatment
effect could not be expected in the absence of effect at
D30.
The evolution of sleep diary data, i.e. sleep efficiency,
total sleep duration, duration of first sleep, number and
duration of night awakenings, number and duration of
nap episodes did not differ between groups.
The investigator Clinical Global Impression change
showed an improvement in 62% of patients in the placebo
group and in 65% of those in the active group (p = 0.52).
Twenty two (44%) patients in the placebo group and
seventeen (33.3%) in the active group had minor adverse
Figure 2 Flow diagram of participants.
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event represented mainly (55%) by headache in both
groups.
Melatonin sub-study
The evolution of urinary melatonin, aMT6S, and of the
Mel/aMT6S ratio showed no differences between the two
groups (all Ps > 0.05, Table 4).
Actigraphic sub-study
Actigraphic data were available in 54 patients out of 61
included. One patient declined to participate and one of
the recordings was not available for five patients. Sleep
efficiency improved similarly in both groups during the
treatment period, from 72% to 76% and 75% in the active
and placebo group respectively (p = 0.91).
Table 2: Primary criterion, D 30-Leeds score
Active Group (n = 50) Placebo Group(n = 49)
Mean (SD) 95% CI Mean (SD) 95% CI
GTS 170.5 (30.7) 161.8; 179.2 173.9 (51.3) 159.2; 188.7
QOS 120.1 (31.4) 111.2; 129 124.8 (41) 113; 136.6
AFS 159.1 (42.6) 147;171.2 161.6 (46.7) 148.2; 175
BFW 118.1 (31.2) 109.2;126.9 118.6 (39.5) 107.3; 129.9
Mean, SD (standard deviation), and 95% confidence interval for GTS (getting to sleep), QOS (quality of sleep), AFS (awaking from sleep), and 
BFW (behaviour following wake) scores in both groups.
Figure 3 Mean score (solid curves and dashed curves) according to age and treatment group for GTS, QOS, AFS and BFW: observed score 
for each patient are also plotted.
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Discussion
The present study showed that the tested dietary supple-
ment did not improve the quality or the duration of sleep
as compared to the olive oil placebo capsules. Further-
more, no significant change of melatonin or aMT6S uri-
nary excretion was observed, suggesting that the dietary
supplement had no effect on the melatonin metabolism.
Potential limitations of the study are first the type of
placebo used. The placebo capsules contained olive oil.
However, it is unlikely that olive oil could have any activ-
ity to improve sleep. No bibliographic references with
both sleep disorders and olive oil have been found. In
their meta-analysis, Mc Call et al. observed a mean dimi-
nution of subjective sleep latency of 13 min, a mean dimi-
nution of polysomnographic latency of 2.5 min, a mean
increase in the total sleep duration of 13 min [27]. These
figures are close to those observed in our placebo group:
15 min and 9 min reduction in the subjective sleep
latency in actigraphic and diary measurements, an 11.5
and a 17 min increase in the total sleep duration mea-
sured by actigraphy and by the sleep diary respectively.
This suggests that our placebo group was a true placebo
group. It is well known that cognitive and compartmental
therapies are effective in mild insomnia. In the present
study, patients had a close follow-up, and were asked to
record a sleep diary. The type of care and follow-up given
during a clinical trial is likely to improve sleep in mild
insomnia, and is an extra justification of the need for pla-
cebo-controlled trials.
The LSEQ questionnaire allowed to measure subjective
ratings of the drug effects on the quality of sleep, early
morning behaviour, and both direction and magnitude of
behavioural changes by using a series of 10 cm line ana-
logue scales. Although the questionnaire was first con-
structed to assess the change after one night, it has been
extensively used for assessing drugs. Zisapel and col. [21]
identified 83 studies that reported the use of the LSEQ for
psychopharmacological investigations of drug effects on
self-reported aspects of sleeping in studies involving a
variety of psychoactive agents in healthy volunteers,
depressed and insomnia patients. The authors concluded
that the LSEQ is a robust and reliable instrument for psy-
Table 3: Secondary criteria: sleep efficiency computed from the sleep diary
Active group (n = 51) Placebo group (n = 50)
Mean (SD)
Sleep efficiency (%)
Week 1 80.9 (13.8) 81.5 (16.6)
Week 4 82.8 (12.7) 85.1 (13.2)
Number of napping episodes
Week 1 0.13 0.11
Week 4 0.13 0.17
General Clinical Impression N (%)
Worsening 1 (2%) 3 (6%)
Unchanged 18 (36%) 14 (29%)
Improved 31 (62%) 32 (65%)
Mean, SD (standard deviation), and 95% confidence interval in both groups.
Table 4: Evolution of urinary melatonin, 6 sulfatoxymelatonin, and melatonin/6 sulfatoxymelatonin ratio
Active group Placebo group
Baseline End of Study Difference Baseline End of Study Difference
Melatonin 
(ng/h),
8.1 (5.9) 10.3 (11.5) +2.2 (11.3) 8.0 (5.4) 7.3 (5.2) -0.7 (5.0)
aMT6S (ng/h) 362.9 (256.0) 333.4 (206.2) -29.4 (138.2) 291.0 (144.4) 294.3 (144.5) +3.3 (111.2)
Mel/aMT6S* 0,0301 
(0,0329)
0,0339 
(0,0327)
+0,004 (0,037) 0,0301 
(0,0201)
0,0319 
(0,0327)
+0,002 (0,030)
Mean (standard deviation)
* mean of all patients ratiosCornu et al. BMC Complementary and Alternative Medicine 2010, 10:29
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chopharmacological evaluations and can provide consis-
tent and meaningful measures for estimating the
effectiveness of sleep modulators and sedative-hypnotic
drugs with various drug regimens, from one day to 24
week-treatment durations [21].
Finding mild therapeutic agents to improve sleep and to
avoid hypnotic drug consumption would be very useful.
Very few studies with adequate methodology have been
performed to assess the impact of dietary supplement
therapies on sleep improvement. In a meta-analysis
including 16 randomised trials and 1093 patients and
summarizing evidence of the effect of valerian, sleep was
improved in significantly more patients (RR: 1.8, 95% CI
= 1.2-2.9), without side effects [28]. However, the authors
found many methodological problems, publication bias,
and considerable variation in valerian doses and prepara-
tions, and treatment duration that led them to conclude
the need for further studies. Melatonin has also shown
clinically meaningful improvements in sleep quality,
morning alertness, sleep onset latency and quality of life
in primary insomnia patients aged over 55 years [11,12].
A fixed combination of valerian and hops was shown to
favourably influence sleep in a similar way as melatonin
[29,30].
The present study was adequately sized and well con-
ducted, since there are very few missing data. It included
clinical and explanatory endpoints, such as melatonin/
aMT6S ratio and actigraphic measurement of sleep
parameters. The study targeted middle age (25-65 years)
subjects with moderate to severe insomnia, who had
never been treated regularly. The age limit was fixed at 25
years, since in younger patients, approximately 10% of
patients with primary insomnia may have delayed sleep
phase syndrome which is sensitive to melatonin treat-
ment [31].
Our results cannot be extended to other types of popu-
lation, e.g. elderly patients who might benefit from such
supplements. Clinical trials specifically designed for these
objectives are warranted.
Recommendations for prescribing hypnotic drugs in
primary insomnia are to advise short period (one week)
use of drugs only if cognitive behavioural therapy is not
effective [32]. However, long-term treatment of insomnia
is sometimes needed. Hypnotic drugs currently available
remain unsatisfying in many cases, because of their insuf-
ficient efficacy and excess of side effects.
Conclusions
The dietary supplement was not found effective in any of
the tested outcomes. New and emerging anti-insomnia
agents may prove useful in the long-term treatment of
chronic insomnia. Further research is needed to establish
the benefit of such treatments.
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